专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009126966A3 GENETIC MARKERS INDICATING BIOLOGICAL RESPONSE TO A PLK1 KINASE INHIBITOR 审中-公开
标题翻译：表达对PLK1激酶抑制剂的生物反应的遗传标记
公开(公告)号：WO2009126966A3
公开(公告)日：2009-12-30
申请号：PCT/US2009040392
申请日：2009-04-13
申请人： UNIV CALIFORNIA , GRAY JOE W , DAS DEBOPRIYA , KUO WEN-LIN , HU ZHI , WANG NICHOLAS J , FEILER HEIDI S , SPELLMAN PAUL T
发明人： GRAY JOE W , DAS DEBOPRIYA , KUO WEN-LIN , HU ZHI , WANG NICHOLAS J , FEILER HEIDI S , SPELLMAN PAUL T
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The invention provides for a method for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a Polo-like kinase inhibitor, such as GSK461364, comprising detecting modulated expression of PLKl and one or more of a set of predictive biomarkers, or protein encoded thereof.
摘要翻译：本发明提供了一种用于鉴定适合用Polo样激酶抑制剂如GSK461364治疗的癌症患者（例如乳腺癌患者）的方法，其包括检测PLK1的调节表达和一组预测性生物标志物或其编码的蛋白质。

2. 发明申请

WO2009055823A3 METHOD TO PREDICT RESPONSIVENESS OF BREAST CANCER TO POLYAMINETYPE CHEMOTHERAPY 审中-公开
标题翻译：预防乳腺癌对聚氨酯治疗的反应方法
公开(公告)号：WO2009055823A3
公开(公告)日：2010-01-07
申请号：PCT/US2008081385
申请日：2008-10-27
申请人： PROGEN PHARMACEUTICALS LTD , UNIV CALIFORNIA , GRAY JOE W , MARTON LAURENCE , DAS DEBOPRYIA , KUO WEN-LIN , WANG NICHOLAS , NEVE RICHARD , SPELLMAN PAUL , FRIDLYAND JANE , CHIN KOEI , HU ZHI
发明人： GRAY JOE W , MARTON LAURENCE , DAS DEBOPRYIA , KUO WEN-LIN , WANG NICHOLAS , NEVE RICHARD , SPELLMAN PAUL , FRIDLYAND JANE , CHIN KOEI , HU ZHI
IPC分类号： G01N33/48 , A61K31/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
摘要： The invention provides for a method for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a conformationally-restricted polyamine, such as CGC-11047, comprising detecting modulated expression of one or more of a set of predictive biomarker genes or proteins in response to treatment with the conformationally-restricted polyamine. The invention further provides for a method of identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype.
摘要翻译：本发明提供了一种用于鉴定适合用构象限制性多胺（例如CGC-11047）治疗的癌症患者例如乳腺癌患者的方法，其包括检测一组或多种预测性生物标记基因的调节表达或蛋白质，以响应用构象限制的多胺处理。本发明进一步提供了鉴定细胞的基底或腔表型的方法，其包括检测一组预测性生物标志物基因或蛋白质中的一种或多种的表达，所述基因或蛋白质鉴定为具有基底或腔内癌症亚型的细胞。

3. 发明申请

WO2006081158A3 PREDICTIVE AND THERAPEUTIC MARKERS IN OVERIAN CANCER 审中-公开
标题翻译：预防和治疗标记在OVERANAN CANCER
公开(公告)号：WO2006081158A3
公开(公告)日：2007-02-01
申请号：PCT/US2006002202
申请日：2006-01-19
申请人： UNIV CALIFORNIA , GRAY JOE W , GUAN YINGHUI , KUO WEN-LIN , FRIDLYAND JANE , MILLS GORDON B
发明人： GRAY JOE W , GUAN YINGHUI , KUO WEN-LIN , FRIDLYAND JANE , MILLS GORDON B
IPC分类号： C12Q1/00 , A01N61/00 , C07H21/02 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/57449 , G01N2800/44 , G01N2800/52
摘要： Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, Ilql3, 20qll-ql3, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVTl, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVTl, target drug resistance in ovarian cancer patients with low survival rates is described.
摘要翻译：可以开发癌症标记物以检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。发现人染色体区域中的基因8q24，Ilql3,20qll-ql3被扩增，表明在诸如卵巢癌之类的疾病中的体内耐药性。扩增级别的诊断和评估显示扩增的某些基因，包括PVT1，可用于预测低存活率的卵巢癌患者患者反应和耐药性差的结果。通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症（特别是卵巢癌）的生存期降低有关，某些基因被认为是高度优先的治疗靶点。描述了抑制这些基因之一的抑制剂的治疗剂，PVT1，具有低存活率的卵巢癌患者中的靶药耐药性。

4. 发明申请

WO2010123608A2 A SPATIAL BIOMARKER OF DISEASE AND DETECTION OF SPATIAL ORGANIZATION OF CELLULAR RECPTORS 审中-公开
标题翻译：一种疾病的空间生物标志物和细胞受体的空间组织探测
公开(公告)号：WO2010123608A2
公开(公告)日：2010-10-28
申请号：PCT/US2010022671
申请日：2010-01-29
申请人： UNIV CALIFORNIA , SALAITA KHALID S , NAIR PRADEEP M , DAS DEBOPRIYA , GRAY JOE W , GROVES JOHN T
发明人： SALAITA KHALID S , NAIR PRADEEP M , DAS DEBOPRIYA , GRAY JOE W , GROVES JOHN T
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： A signature of a condition of a live cell is established in an assay that allows distribution of the receptors on the cell surface in response to binding a ligand. The receptors can be optically detected and quantified to provide a value for the condition, Test drugs can be screened for therapeutic potential in the assay: a potentially efficacious drug is identified by an ability to modulate an established signature. The receptor distribution signature can be corroborated with an mRNA expression profile of several genes, indicating, for example, metastasis.
摘要翻译：在允许响应于结合配体而分布细胞表面上的受体的测定中建立活细胞状况的特征。可以对受体进行光学检测和定量以提供该病症的值。可以在测定中筛选测试药物的治疗潜力：潜在有效的药物通过调节已建立的特征的能力来鉴定。受体分布特征可以用几种基因的mRNA表达谱来证实，表明例如转移。

5. 发明申请

WO2007143752A3 TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY 审中-公开
标题翻译：乳腺癌中的目标用于预防或治疗
公开(公告)号：WO2007143752A3
公开(公告)日：2008-09-25
申请号：PCT/US2007070908
申请日：2007-06-11
申请人： UNIV CALIFORNIA , GRAY JOE W , FRIDLYAND JANE , NEVE RICHARD , SPELLMAN PAUL , CHIN KOEI , HU ZHI , WALDMAN FREDERIC
发明人： GRAY JOE W , FRIDLYAND JANE , NEVE RICHARD , SPELLMAN PAUL , CHIN KOEI , HU ZHI , WALDMAN FREDERIC
IPC分类号： C12P19/34 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8pl 1, 1 Iql3, 17ql2, and 20ql3 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
摘要翻译：癌症标志物被开发用于检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。基因组分析的乳腺癌基因组拷贝数和基因表达显示人类染色体区域中的66个基因，扩增出8pl1,1Iql3,17q2和20ql3。显示为扩增的基因的扩增水平的诊断和评估可用于预测患者在乳腺癌中的反应和耐药性的结果。通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症特别是乳腺癌中的存活时间减少有关，某些基因被认为是高度优先的治疗靶点。这些基因的抑制剂将是治疗这些非反应性癌症的有用治疗方法。

6. 发明申请

WO0192558A3 END SEQUENCE PROFILING 审中-公开
标题翻译：端序列分析
公开(公告)号：WO0192558A3
公开(公告)日：2002-04-04
申请号：PCT/US0117757
申请日：2001-05-31
申请人： UNIV CALIFORNIA , COLLINS COLIN , VOLIK STANISLAV , GRAY JOE W
发明人： COLLINS COLIN , VOLIK STANISLAV , GRAY JOE W
IPC分类号： C12Q1/68 , G01N31/00 , G06F17/00
CPC分类号： C12Q1/6869 , C12Q1/6827
摘要： The present invention provides a novel method to identify rearrangements in a test genome, e.g., a tumor genome, when compared to a reference genome. This method provides major improvements over previous methods in terms of efficiency, rapidity, and cost-effectiveness. Briefly, this method involves generating or obtaining a large insert vector library from a test genome, sequencing the ends of the inserts in the library, and comparing the co-linearity of the sequenced ends in the library with corresponding sequences within a substantially-sequenced reference genome. This invention is useful for any of a number of applications, including for identifying rearrangements in tumor genomes and for determining genetic differences between closely related species as well as between different strains of the same species.
摘要翻译：当与参考基因组相比时，本发明提供了鉴定测试基因组例如肿瘤基因组中的重排的新方法。这种方法在效率，快速性和成本效益方面提供了相对于以前方法的重大改进。简而言之，该方法涉及从测试基因组产生或获得大的插入载体文库，对文库中插入片段的末端进行测序，并将文库中测序末端的共线性与基本测序的参考中的相应序列进行比较基因组。本发明可用于许多应用中的任何一种，包括用于鉴定肿瘤基因组中的重排以及用于确定密切相关物种之间以及相同物种的不同菌株之间的遗传差异。

7. 发明申请

WO2009045579A3 MULTIMODAL IMAGING PROBES FOR IN VIVO TARGETED AND NON-TARGETED IMAGING AND THERAPEUTICS 审中-公开
标题翻译：多目标成像和非目标成像和治疗方法的多模式成像探针
公开(公告)号：WO2009045579A3
公开(公告)日：2010-01-07
申请号：PCT/US2008067009
申请日：2008-06-13
申请人： UNIV CALIFORNIA , CHEN FANQING FRANK , GERION DANIELE , GRAY JOE W , BUDINGER THOMAS F
发明人： CHEN FANQING FRANK , GERION DANIELE , GRAY JOE W , BUDINGER THOMAS F
IPC分类号： B32B5/16 , B32B9/00 , B32B15/02 , B32B17/02 , B32B19/00 , B32B21/02 , B32B23/02
CPC分类号： G01N21/6428 , A61K41/0071 , A61K47/6923 , A61K47/6929 , A61K49/0002 , A61K49/0065 , A61K49/0067 , A61K49/085 , A61K49/106 , A61K49/1881 , A61K51/1244 , B82Y5/00
摘要： In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells.
摘要翻译：在某些实施方案中，本发明提供了一种用于多峰体内成像和治疗的基于纳米颗粒的技术平台。基于纳米颗粒的探针通过MRI，PET或深部组织近红外（NIR）成像来检测患病细胞，并且能够以比现有技术可能更高的灵敏度检测患病细胞。探针还靶向定位于正常或患病细胞的分子，并引发患病细胞的凋亡。

8. 发明申请

WO2005007097A3 BREAST CANCER GENES 审中-公开
标题翻译：乳腺癌基因
公开(公告)号：WO2005007097A3
公开(公告)日：2005-10-06
申请号：PCT/US2004021778
申请日：2004-07-06
申请人： UNIV CALIFORNIA , GRAY JOE W , NEVE RICHARD M , MCCORMICK FRANK , YEH JENNIFER , CHIN KOEI , MACRAE MADHU
发明人： GRAY JOE W , NEVE RICHARD M , MCCORMICK FRANK , YEH JENNIFER , CHIN KOEI , MACRAE MADHU
IPC分类号： C12Q1/68 , G01N33/50 , G01N33/574 , C12Q1/00 , G01N33/48 , G01N33/53 , G01N33/567
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/5011 , G01N2800/52
摘要： This invention is based upon the discovery that EPHA2, BAG4, and ARF1 are amplified and overexpressed in cancer. The present invention therefore provides methods, reagents, and kits for diagnosing and treating breast cancer.
摘要翻译：本发明基于EPHA2，BAG4和ARF1在癌症中被扩增和过表达的发现。因此，本发明提供了用于诊断和治疗乳腺癌的方法，试剂和试剂盒。

9. 发明申请

WO2007084962A3 A FLUID MEMBRANE-BASED LIGAND DISPLAY SYSTEM FOR LIVE CELL ASSAYS AND DISEASE DIAGNOSIS APPLICATIONS 审中-公开
标题翻译：用于活细胞测定和疾病诊断应用的基于流体膜的配体显示系统
公开(公告)号：WO2007084962A3
公开(公告)日：2009-02-26
申请号：PCT/US2007060721
申请日：2007-01-18
申请人： UNIV CALIFORNIA , NAM JWA-MIN , NAIR PRADEEP M , NEVE RICHARD M , GRAY JOE W , GROVES JOHN T
发明人： NAM JWA-MIN , NAIR PRADEEP M , NEVE RICHARD M , GRAY JOE W , GROVES JOHN T
IPC分类号： A61K9/127
CPC分类号： G01N33/554
摘要： A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin Al to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format.
摘要翻译：描述了一种用于向活细胞呈递可溶性信号分子的支持膜的策略。在该系统中，支持的膜的流动性使得能够在反映细胞表面上的同源受体分布的构型中局部富集配体密度。在非流体支持的膜中显示配体产生显着更少的细胞粘附和扩散，因此证明该技术提供了以表面阵列形式控制功能性可溶性配体暴露的方法。此外，这种技术可以应用于系统地将膜结合的信号分子例如ephrin A1应用于支持的脂质双层。这种表面可以调节显示配体和选择的生物分子的转移性人乳腺癌细胞的扩散行为。 SLB微环境提供了一个通用平台，可以进行调整，以便可控地和功能地呈现并行表面阵列格式的多个单元信令事件。

10. 发明申请

WO2007124314A2 USE OF ORGANIC CATION TRANSPORTERS FOR CANCER DIAGNOSIS AND THERAPY 审中-公开
标题翻译：有机摄影机使用癌症诊断和治疗方法
公开(公告)号：WO2007124314A2
公开(公告)日：2007-11-01
申请号：PCT/US2007066848
申请日：2007-04-18
申请人： UNIV CALIFORNIA , GIACOMINI KATHLEEN M , GRAY JOE W , LAPUK ANNA , ZHANG SHUZHONG
发明人： GIACOMINI KATHLEEN M , GRAY JOE W , LAPUK ANNA , ZHANG SHUZHONG
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , G01N33/57407 , G01N33/57492 , G01N2800/52
摘要： The present invention provides, for the first time, the finding that organic cation transporters (OCTs) are major determinants of the anticancer activity of platinum-based drugs such as oxaliplatin, and therefore have clinical significance for selecting oxaliplatin as the preferred therapy for a cancer that expresses one or more OCTs, such as colorectal cancer or liver cancer. In addition, the OCT genotype can also be used to predict oxaliplatin response or to select therapy. The present invention also provides methods of treating or inhibiting cancers that expresses one or more OCTs by administering a therapeutically effective amount of a platinum-based drug such as an oxaliplatin analog having an organic non-leaving group with an increased size. The present invention further provides methods of sensitizing a therapy resistant cancer to a platinum-based drug such as oxaliplatin by administering a therapeutically effective amount of a nucleic acid encoding an OCT. Compositions, kits, and integrated systems for carrying out the diagnostic, prognostic, and therapeutic methods of the present invention are also provided.
摘要翻译：本发明首次提供了有机阳离子转运蛋白（OCT）是铂类药物如奥沙利铂的抗癌活性的主要决定因素，因此对于选择奥沙利铂作为癌症的优选治疗具有临床意义其表达一个或多个OCT，例如结肠直肠癌或肝癌。此外，OCT基因型也可用于预测奥沙利铂反应或选择治疗。本发明还提供了通过施用治疗有效量的具有增加大小的具有有机非离去基团的奥沙利铂类似物的铂基药物来治疗或抑制表达一种或多种OCT的癌症的方法。本发明进一步提供了通过施用治疗有效量的编码OCT的核酸来使耐药性癌症对铂类药物例如奥沙利铂敏感的方法。还提供了用于实施本发明的诊断，预后和治疗方法的组合物，试剂盒和综合系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式